Please assess the completion status of the following clinical trial:

Trial Title: High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 19 to 75 years~2. Patients diagnosed with ASCVD (coronary artery disease)~   * acute coronary syndrome~  * history of myocardial infarction (MI)~  * stable or unstable angina~  * history of coronary revascularization~  * stroke or transient ischemic attack (TIA)~  * peripheral arterial disease, history of peripheral arterial revascularization~3. Taking a stable dose of a statin or a lipid-lowering agent of ezetimibe over 4 weeks before randomization~4. Written informed consent~Exclusion Criteria:~1. Administration of other lipid lowering agents than statin or ezetimibe within 3 months prior to screening visit~2. Fasting triglyceride ≥ 400 mg/dL~3. History of muscular disease or rhabdomyolysis due to use of statin~4. Hypersensitive to rosuvastatin or ezetemibe~5. Contraindications stated in the SPC of rosuvastatin or rosuvastatin/ezetimibe including the following:~   ① Severe renal disease (CrCL \< 30mL/min: Cockcroft-gault formula or estimated GFR (MDRD) \< 30mL/min/1.73m2)~   ② ALT, AST \> 3x ULN or history of active liver disease~   ③ CPK \> 3x ULN~6. Administration of other investigational products within 30 days prior to screening visit~7. Other than the above who is deemed to be ineligible to participate in the trial by investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvamibe Tab (Type: EXPERIMENTAL): Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
- Monorova Tab (Type: ACTIVE_COMPARATOR): Rosuvastatin 20mg qd for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).